Praxis Precision Medicines, Inc.
PRAX
株式のランク
#2584
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
株価
$264.54
時価総額
$7.39B
変化（1日）
1.68%
変化（1年）
51.11%
国
US
取引 Praxis Precision Medicines, Inc. (PRAX)
カテゴリー
Healthcare
Praxis Precision Medicines, Inc.（PRAX）のP/E比率
October 2026 時点のP/E比率 TTM -18.46
Praxis Precision Medicines, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -18.46 です。2023 年末時点での P/E は -1.19 でした。
Praxis Precision Medicines, Inc. の P/E 比率の履歴（2018 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -18.46 | 144.79% |
| 2024 | -7.54 | 532.50% |
| 2023 | -1.19 | 131.46% |
| 2022 | -0.51 | -89.73% |
| 2021 | -5.01 | -37.08% |
| 2020 | -7.97 | 565.25% |
| 2019 | -1.20 | -11.92% |
| 2018 | -1.36 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -255.94% |
US
|
|
| -28.36 | 53.64% |
US
|
|
| -24.57 | 33.10% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -264.33% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。